This reading list we received from Drs entirely disinterested. E. Valstar, (Orthomolecular) doctor / biologist. We provide this list are unchanged for publication. .
Scroll down for list.
Valstar wrote the book Nutritional intervention in cancer, a signal to the conventional oncology. See description on page, etc. ISBN cancer rates. We want to mention that we have no business or substantive ties with Engelbert Valstar, but this book and lists seem to us so interesting that we want to change places. Questions / comments can be sent to the editor: redactie@kanker-actueel.nl We will keep your questions / comments to be forwarded Valstar. Also on this list and further information on this page is of course our disclaimer applies.
More detailed descriptions and other studies see and nutrition research. And we try to at least the abstract and the results of the Phase III trials and pivotal Phase II studies in the literature list and nutrition research. or current mainstream research to publish or not fitted comments.
For regular treatments in general because the only randomized study possible side effects. Moreover, a randomized study of conventional treatments often never implemented. This assertion of Valstar based on relevant literature is in NTvG (see NTvG 136: 709-710, 1992) by the respective oncologists not contradicted.
See also Nutritional Oncology, Heber D. et al ISBN 0-12-335960-0, the book was edited by Harvard and by the Memorial Sloan Kettering Institute! ).
(Editors note: See extensive bibliography in the book of Valstar Nutritional intervention in cancer, a signal to the conventional oncology and now as published on this site)..
To this list are Hans Houtsmuller, Ed Woerlee Johan Bolhuis and important contributions.
Bibliography of studies cancer and nutrition / supplementation. Studies: 601 t / m 700
601) Melekos MD et al, Int Urol Nephrol 28: 499-509, 1996, BCG appears in this randomized study as an additional adjuvant to treat bladder cancer more effective than epirubicin alone, as far as the more aggressive type of bladder cancer concerns
602) Rintala E et al, J Urol 156: 56-9, 1996, in this randomized study were alternating BCG and mitomycin C as effective as an additional adjuvant for treatment of bladder cancer as mitomycin C-sec
603) M Ashraf et al, Gynecol Oncol 37: 29-33, 1990; Magnesium is randomized study the effects of cisplatin on the nervous system.
604) Balmer PE, Reinhart WH, Cancer Chemother Pharmacol 24: 109-12, 1989; In this randomized study shows magnesium in the application of cisplatin no anti-emetic effect.
605) IU Gruenwald et al, J Urol 157 :487-91, 1997, 12 weeks would be more flush with BCG as adjuvant therapy after resection superficial bladder cancer than 6 weeks of adjunctive therapy with BCG.
606) Jiménez-Cruz JF et al, Urology 50 :529-35, 1997, BCG is local recurrence in randomized studies against bladder cancer more effectively than interferon.
607) G Smits et al, Urology 52 :1009-13, 1998; In this randomized study, mitomycin-C as well as additional adjuvant in the treatment of bladder cancer and BCG.
608) Witjes JA et al, J Urol 160 :1668-71, 1998; In this randomized study, BCG and mitomycin C as well as additional adjuvant for the treatment of bladder cancer.
609) F Yalcin Kaya et al, Int Urol Nephrol 30 :41-4, 1998, the most common dose BCG appears as an adjuvant in the treatment of bladder cancer more effectively than in this study also tested lower doses.
610) Malmstrom M et al, J Urol 161: 1124-7, 1999, BCG was found in this large randomized study as an adjunct in the treatment of bladder cancer more effectively than mitomycin-C.
611) Palou J et al, J Urol 165: 1488-1491, 2001, as an additional adjuvant BCG in the treatment of bladder cancer in the default setup gives an equally good result as in the standard design and a maintenance dose of BCG.
612) Eaton JD et al, BJU Int 89 :19-26, 2002, Vaccination of patients with prostate cancer cell line plus Mycobacterium vaccae resulted in randomized studies to marked immune stimulation, in some patients decreased PSA, which is not as spontaneous qualified could be.
613) Assersohn L et al, Clin Oncol (R Coll Radiol) :23-14 July, 2002, with heat-treated Mycobacterium vaccae gives extra life prolongation in patients with small cell lung cancer that also chemotherapeutic treatment. See also reference 353.
614) Decroix G et al, Cancer 53: 906-12; Killed Mycobacterium smegmatis improves prognosis of patients operated for non-small cell lung cancer is not.
615) Van der Meijden AP et al, J Urol 166: 476-81, 2001, BCG is this very large study (almost 1000 patients) to treat bladder cancer demonstrably more effective than epirubicin.
616) R Powles and JL Toy, Haematologia 10 :5-9, 1976, BCG prolongs the lives of patients with AML who are treated with chemotherapy significantly in this randomized study.
617) JA Whittaker and AJ Slater, Br J Haematol 35 :263-73, 1977; Intravenous BCG randomized study improves survival in patients with AML who responded to initial chemotherapy had.
618) Proud D et al, Sem Hop 55: 633-8, 1979, after complete remission of AML BCG appears to improve survival significantly, as confirmed by this randomized study.
619) Vuvan H et al, Scand J Heamatol 21: 40-6, 1978; BCG as adjuvant chemo improves survival in ANLL in this study, it is possible with the significantly greater risk of regression to second-line chemotherapy.
620) Summerfield GP et al, Br J Cancer 40 :736-42, 1979, in AML Chemo plus BCG provides a significantly longer survival than chemotherapy alone, presumably this is due to the signifcant fewer recurrences of AML in the brains of patients who received BCG.
621) Hewlett JS et al, Arch Intern Med 145: 1006-1012, 1985; BCG first partially successful induction chemotherapy improves data shows the median survival of AML not.
622) Travel Stein P, Br J Haematol 75: 288-9, 1990; BCG randomized study shows the prognosis of AML improve.
623) Zuhrie SR et al, Br J Cancer 41: 372-7, 1980, in remission after first line shows the period of the BCG demonstrated to prolong remission and survival duration, study numbers 447, 562, 616, 617, 618, 620, 622 and 623 showAML with a better prognosis seen with BCG, only at number 621 (one small study) is not the case, a trivial meta-analysis of these studies together show that BCG's prognosis AML.
624) Anderson PM et al, Bone Marrow Transplant 22: 339-44, 1998, Glutamine reduces randomized, double-blind study oral pain associated with bone marrow transplantation and is therefore combined with a reduced opiate use, survival after one month was glutamine arguably better though there is no statistical effect of glutamine on the course of the cancer.
625) N Piccirillo et al, Haematologica 88: 192-200, 2003; In this randomized study in patients who have had a peripheral stem cell transplantation, L-glutamine is the occurrence of mucositis against. .
626) Kozelsky TF et al, J Clin Oncol 21 :1669-74, 2003, glutamine is in this randomized, double-blind study the occurrence of diarrhea due to irradiation of the pelvis. .
627) Castel T et al, Dermatologica 183 :25-30, 1991; BCG in addition to chemotherapy improves the prognosis of melanoma of the leg stage 1 or 2 over adjuvant chemotherapy as the only ..
628) Cascinelli N et al 28 :282-6, 1989, BCG improves survival in this randomized study of patients at high risk of recurrence of melanoma for which they are treated if they were significant in the beginning had a negative Mantoux reaction . .
629) and Z Mechl Kopechny J; Arch Geschwulstforsc 56: 367-71, 1986; improved BCG as adjuvant in this study in melanoma patients treated surgically or stage 2 disease-free survival or the survival sec. .
630) Pinsky CM et al, Ann New York Acad Sci 277 :187-194, 1996, in this small study (24 vs. 23), patients treated for a stage 2 melanoma with BCG has no demonstrable benefit with regard to life expectancy found ..
631) Kostinas JE et al, Cancer Treat Rep 63: 197-200, 1979; An alcohol extract of BCG improves the outcome of chemotherapy in patients with melanoma stage 3 or 4 in terms of both response rate and survival do not. .
632) Samuels ML et al, Cancer Treatment Rep. 65: 615-27; Intravenous hyper maintenance in patients with metastatic testicular cancer that receive chemotherapy increases the risk of life-threatening infections, this study supports the hypothesis that extra calories like better for cancer than for the patient.
633) Shamberger RC et al, Am J Med 74: 40-8, 1983; Patients with bone cancer who receive chemotherapy are treated with TPN significantly more calories, it increases include their transfusion requirements were significantly increased, again no extra calories! .
634) Christensen ML et al, Cancer 72 :2732-8, 1993 "In this study with (single compound) TPN no benefit seen in children with cancer who receive chemotherapy, on the contrary: ie, there are arguably more infections, which is not only 632 but also by meta-analysis confirms, once again get their orthomoleculairen the same, see also 633 and 11 (in the latter study has precisely caloric restriction on long-term therapeutic effects) ..
635) Nixon DW et al, Cancer Detect Prev. 4 :421-7, 1981, TPN with hypertonic sugar solution with amino acids shown in patients with an advanced form of colon cancer significantly shorten life, what you see above references and in particular the animal experimental literature would expect ..
636) Paterson AH et al, Can Med Assoc J 131 :744-8, 1984; Partly intradermal BCG given partly orally after surgery improves the prognosis of melanoma patients stage 1 is not significant.
637) McLean IW, et al, Am J Ophtalmol 110: 522-6, 1990, after surgery for a melanoma uveaal shows a methanol extract of BCG did not improve the prognosis.
638) CF Verschraegen et al, Eur J Cancer 29A :708-11, 1993, a methanol-based extraction of BCG preparation improves the prognosis of melanoma patients, chemotherapy is not treated.
639) DA de Luis et al, Eur J Clin Nutr 56: 1126-9, 2002, arginine plus fiber impaired in patients due to throat cancer surgery, the risk of developing fistulas.
640) Karakousis CP, and LJ Emrich, J Surg Oncol 36: 235-8, 1987; BCG as adjuvant after surgery for a melanoma improves survival is not.
641) Sterchi JM et al, Cancer 55: 707-12, 1985, BCG plus dacarbazine shows as adjuvant after surgery for a melanoma stage 1 or 2 with no better prognosis than carbazine alone as adjuvant.
642) BM Czarnetzki et al, Eur J Cancer 29A: 1237-1242, 1993; Various BCG preparations improve the prognosis of melanoma patients stage 1 is not. The following numbers relate to BCG and melanoma (most adjuvantstudies): 382,385,460, 548,549, 550, 551, 553, 554, 556, 627, 628, 629, 630, 631, 636, 637, 638, 639, 641 and 642. In one study, a better response to chemotherapy seen (548), a significantly better prognosis was seen in only 3 studies (550 553 and 628), just seen the weight of the (sub) trials, BCG is not statistically significant option. Well, of course, at least in AML and bladder cancer.
643) A. Adler et al, J Biol Response Mod 6: 610-24, 1987; BCG improves randomized study of patients operated for kidney cancer which is also hormone therapy.
644) MF Brennan et al, Ann Surg 220: 436-41, 1994; TPN (extra food) increases in surgery for pancreatic cancer in randomized study the risk of complications (especially infections).
645) Fasth S et al, Int J Colorectal Dis 2 :87-92, 1987, TPN appears to surgery for colon cancer the risk of complications can not be reduced, this result is again consistent with the ideas of mine, Moerman et al
646) E Harju et al, Chir Ital 42: 151-64, 1990; extra protein through TPN, in patients without prior protein deficiency due to colon cancer and need surgery, therefore experience more complications. Orthomolecular commits Such patients show no additional protein; prudent given this result.
647) Heys SD et al, Br J Surg 78: 483-7, 1991; Caloric restriction appears in vivo randomized study in cancer patients pre-operatively coupled to a slower tumor growth.
648) Akihama T et al; Gan To Kagaku Ryoho 10 :2125-9, 1983; Q10 comes in randomized double-blind study in patients with leukemia / malignant lymphoma the onset of liver function by anthracyclines against, hair loss by these means is Q10 does not arguably prevented.
649) Mathe G et al, Proc R Soc Med 68: 211-6, 1975: Corynebacterium parvum ALL after chemotherapy because of late long-term patients in more than Corynebacterium parvum regression is not given.
650) H Toomes et al, Dtsch Med Wochenschr 109: 935-40, 1984; Failure NSCLC shows postoperative intrapleural Corynebacterium parvum administered long-term mortality rates; with BCG is administered in the same way no beneficial effect achieved.
651) JW Millar et al, Thorax 35: 856-8, 1980; Malignant pleural effusion with Corynebacterium parvum significantly better than treatment with mustine and provides far fewer side effects than mustine.
652) Galligioni E et al, Cancer 77 :2560-6, 1996: The combination of autologous tumor cells with BCG improves prognosis in renal cancer is not, see 643.
653) Robinson E et al, Cancer 40 :1052-9, 1977, BCG (based on a methanol extract) shown in this randomized study in patients with advanced lung cancer the number of distant metastases significantly lower, life is but just not significantly prolonged.
654) Anthony HM et al, Cancer 42: 1784-1792, 1978; BCG appears in inoperable lung cancer patients (before randomization was stratified first) the quality of life significantly improved, life was not significantly extended life after radiation, this extension is very significant.
655) McKneally MF et al, Lancet 1 (7956): 377-9, 1976; given intrapleural BCG in stage 1 appears to reduce lung cancer mortality, although isoniazid was given as to the likelihood of TB by BCG costs.
656) McKneally MF et al, J Thorac Cardiovasc Surg 72: 333-8, 1976; intrapleural BCG with isoniazid improves prognosis stage 1 lung cancer patients.
657) Macchiarini P et al, Anticancer Res 9: 391-3, 1989; In a small randomized trial (17 vs. 17) showed BCG as an adjuvant in patients operated on for lung cancer stage 1 disease-free survival, median survival and 5-year survival is not significantly improve, it is clear that with such small numbers of significance is difficult to weigh, we later make an overall analysis separately for stage 1, 2 plus 3 and operated for inoperable lung cancer.
658) Macchiarini P et al, Am J Clin Oncol 14: 291-7, 1991; In lung cancer patients, stage 2 / 3 who already receive chemotherapy after surgery shows BCG disease-free survival / survival s not only significantly improve.
659) Maurer LH et al: J Clin Oncol 3: 969-76, 1985, a methanol-based extraction BCG preparation (not so live) shows thetreatment of small cell lung cancer with chemotherapy and radiation, no additional value.
660) Feld R et al, J Clin Oncol 2: 1352-8, 1984, this large randomized trial in lung cancer patients stage 1 non-small cell (473 patients) was given intrapleural BCG disease-free survival was not significantly improve.
661) McKneally MF et al, J Thorac Cardiovasc Surg 81 :485-92, 1981, in 169 patients with stage 1 lung cancer was based on randomized intrapleural BCG or given anything extra, after 3 years were in the BCG group, 33% recurrences, while the percentage in the control group was 66, a highly significant difference.
662) LLCSG, Cancer 58: 2411-6, 1986; In this randomized study in patients operated on for lung cancer stage 1 or 2 was given intrapleural BCG not to influence the prognosis.
663) Little AG et al, Surgery 100 :621-8, 1986, BCG was found after surgery for lung cancer stage 1 / 2 sided statistically measured to an improved 5-year survival procedure.
664) Hubay CA et al, Surgery 87: 494-501, 1980; In patients with positive estrogen receptor enhances tamoxifen plus BCG disease-free survival over tamoxifen alone, in patients with negative estrogen receptor measurement was not found.
665) Gail MH, Chest 106 (6Suppl): 287S-92S, 1994, 473 patients with lung cancer were stage 1 or 2 in a randomized trial of saline as control, with no BCG better disease-free survival or survival to have seconds.
666) Hoover HC et al, J Clin Oncol 11: 390-9, 1993; BCG plus autologous cancer cells (ASI therapy) improves in colon cancer patients after surgery or disease-free survival and survival sec, except in cases of rectal cancer by latter may be due right after the immunotherapy was also irradiated.
667) EA Abdi et al, J Surg Oncol 40: 205-13, 1989; BCG improves disease-free survival of patients operated due to colon cancer Dukes' B2 or C, this effect is less significant when adjuvantchemo also given.
668) Hoover HC et al, Cancer 55 :1236-43, 1985, BCG plus autologous cancer cells (ASI therapy) gives in this randomized study in cancer patients a better disease-free survival and survival sec.
669) JE Harris et al, J Clin Oncol 18: 148-57, 2000, BCG plus autologous cancer cells in colorectal cancer patients improves stage 2 / 3 with only one-tailed trend for disease-free survival.
670) Robinson E et al: Recent Results Cancer Res 75: 80-7, 1980, in this randomized study in cancer patients appears BCG sense, now extract methanol-based prepared: disease-free survival and survival seconds after 2 years better the BCG group.
671) JE Harris et al, J Clin Oncol 18: 148-57, 2000; In this randomized study with BCG according to the ASI-method is no effect on the prognosis of patients operated for colon cancer stage 2 / 3.
672) Gray BN et al, J Surg Oncol 40: 34-7, 1989; with BCG according to the ASI method used in this study in colorectal cancer patients operated on for colon cancer stage 2 / 3 no improvement in prognosis achieved.
673) Ambus U et al, Dev Biol Stand 38 :541-5, 1977, BCG besides 5-FU improves the prognosis of cancer patients, stage 2 / 3 compared with 5-FU significantly as the only adjuvant therapy in cases of inoperable colon cancer in addition to BCG 5-FU no additional value.
674) GA Higgins et al, Cancer 54: 193-8, 1984: A BCG extract prepared with methanol as an additional adjuvant improves next 5-FU and methyl-CCNU improves the prognosis of cancer patients whose tumors could not be fully removed not.
675) Hoover HC, Hanna MG, Semin Surg Oncol 5: 436-40, 1989; In colon cancer patients operated for Dukes'B2 C3-ASI approach improves both the BCG disease-free survival and survival sec.
676) Richards F 2nd et al, Cancer 43 :91-6, 1979; In metastatic colorectal cancer improves BCG prepared methanol basis (an extract dead!) The result of vincristine, methotrexate and methyl-CCNU not.
677) No authors listed; N Engl J Med 310: 737-43; A BCG extract prepared based on methanol improves outcome of adjuvant 5-FU and semustine in patients operated on for Dukes' stage C colon cancer is not. Here is a list of cancer / BCG. In 2 studies (674 and 676) was not only curative surgery exists: there is not helped BCG. In the 12 other studies (377,378,666,667,668,669,670,671,672, 673,675 and 677 showed BCG in 10 of the 12 meaningful, we look only at the ASI method (7 out of 12 trials) than was BCGin 6 of 7 studies of significant value. BCG's and certainly by the ASI method as a useful adjunct in the treatment of colon cancer stage 2 / 3. We saw earlier that BCG is useful in advanced prostate cancer, bladder cancer onset and AML (thereby superior to chemotherapy), for kidney cancer is unclear and the usefulness of BCG in malignant melanoma BCG at all meaningful.
678) No authors listed; J Thorac Cardiovasc Surg 82 :649-57, 1981; intrapleural BCG given in this randomized study shows the prognosis of operated lung cancer patients do not improve, this was also true separately for stage-1 patients.
679) Roeslin N et al, Cancer Immunol Immunother 13 :174-5, 1982; Intradermal administration of BCG as an adjuvant for patients operated for squamous cell carcinoma of the lung in this randomized study improves the prognosis is not.
680) Roeslin N et al, Eur J Cardiothorac Surg 3: 430-5, 1989; intrapleural administration of BCG in patients because of non-small cell lung cancer surgery in this study thus appear not to have better prognosis.
681) Senn HJ et al, Adjuvant chemotherapy plus BCG in women who had surgery for breast glands zero indicate a better disease-free survival than chemotherapy alone.
682) Millar JW et al, Thorax 37 :57-60, 1982; In 92 patients with lung cancer were three groups randomized base 2 different BCG infusions with nothing extra compared, disease-free survival and the survival sec appeared after 5 same year for all 3 groups.
683) Balch CM et al, Cancer 49 :1079-84, 1982, Corynebacterium parvum (Cp) and immuno-adjuvant improves disease-free survival and survival of melanoma patients with sec a primary tumor of 3 mm or more. See also 382, Cp increases in 2 studies disease-free survival stage 2 (382 and 383, the latter was by immunotherapy, the survival seconds better), in 460 was for Cp no effect besides intensive adjuvantchemo, while in 384 the effect of cp on survival in the adjuvantsituatie not only significantly positive. Three studies are significantly positive and certainly a non-significant positive. My preliminary conclusion is overall-Cp is suitable as an adjunct for treatment of a potentially curative treatment malignant melanoma. In case of metastatic melanoma is different, see below.
684) Kokoschka EM et al; Onkologie 1: 98-103, 1978; Patients with metastatic melanoma cancer were methyl-CCNU or not pretreated with Corynebacterium parvum, Corynebacterium parvum with there were more regressions and survival was longer.
685) Lowe J et al, Lancet! (8158) :11-4, 1980, in a randomized trial in 92 patients after surgery for lung cancer appears intrapleural BCG given no clear effect on survival to have.
686) Matthay RA et al, Cancer Res 46: 5963-8, 1986; Preoperative BCG into the lung tumor had no effect on survival or disease-free survival in patients with this cancer s, which went to surgery.
687) Rosso R et al, Treatment of Tumors 68 :527-30, 1982, In advanced oat-cell lung cancer chemo seems more unfavorable than favorable. An overview of BCG and lung cancer is now following, we look at the studies with small cell lung cancer: In 409 and 659 with a dead BCG vaccine does not affect the forecast brings about, with a live vaccine that works (408).
For unresectable large cell lung cancers seen in one study (653) an inhibition of further metastasis, but no effect on survival, in another study in which the quality of life is viewed (654) we see with BCG better quality of life and with BCG alone life extension if there is a locally unresectable tumor is irradiated, in yet another study of lung cancer patients in advanced stages seen after complete regression of life extension by BCG in the remaining four studies suggest at all, no effect on survival (351,355,411 and 687). In short, large cell lung cancer is inoperable BCG only interesting as a useful local radiation treatment or some other treatment already achieved a complete regression or BCG is the inoperable large cell lung cancer usually does not make sense.
Operated as an adjunct for lung cancer is BCG tested in 17 trials (557, 650,655,656, 657,658,660,661,662,663,665,678, 679,680, 682, 685 and 686), in nine studies explicitly (eg) to stage a look (655,656,657,660,661,662,663,665 en678), only five have a better prognosis see only the two largest studies are not (665 and 678), BCG may have at this stage although no preciseMeta-analysis is needed to settle the matter, then to BCG in stage 1 as an adjuvant for me the benefit of the doubt.
As an adjunct in (among others) stage 2 / 3 after surgery in 10 studies tested BCG (557,650,658,662,663,679,680,682, 685 and 686), the result was not only two large studies such as the forecast concerns positive (662 and 663), while in study 663 stage 1 may have played a part and the result was only partially positive: my conclusion is that BCG as adjuvant in stage 2 / 3 after surgery is useless.
688) SP Richman et al, Cancer Treatm Rep 60: 535-9, 1976, in patients with recurrent throat BCG showed intensive chemotherapy in addition to prolonging life.
689) Taylor SG 4th et al, Arch Otolaryngol 109: 544-9, 1983; In patients with "locally advanced" but to treat throat cancer received intensive treatment with BCG, which resulted in improved disease-free survival and survival sec.
690) Woods JE et al, Surg Clin North Am 57: 769-78, 1977; BCG shows the result of methotrexate in patients with advanced throat cancer was not significantly improve.
691) Isenberg J et al, Anticancer Res 14: 1399-404, 1994, Propionibacterium granulosum given beforehand reduces the risk of postoperative infection, in stage 1 and 2 also showed improved survival.
692) Agarwala SS et al, Cancer 100: 1692-8, 2004, BCG as an additional adjuvant or any adjuvant improves long-term prognosis of melanoma patients, stage 1 / 2 not, which I also previously concluded.
693) Watanabe M et al, Int J Clin Oncol 9: 98-106, 2004, OK-432 as an additional adjuvant chemo improves the prognosis of patients operated due to colorectal tumor. for example, gastric cancer is OK-432 does.
694) K. Shirabe et al, Hepatogastroenterology 44: 205-9, 1997; TPN reduces quality immunological parameters after surgery for liver cancer, the risk of infection increased as a result of this study is not significantly increased, and another one in line with earlier references in this list.
695) Britell JC et al, Cancer Clin Trials 2, 345-50, 1979; A methanol extract of BCG improves outcome of 5-FU, cyclophosphamide and prednisone in patients with advanced breast cancer is not.
696) Ferreira PR et al, Head Neck 26: 313-21, 2004, Vitamin E reduces mucositis as a side effect of radiation due to throat cancer.
697) Poon RT et al, Aliment Pharmacol Ther 19: 779-88, 2004; BCAA reduce morbidity and improve quality of life of patients who undergo chemoembolisatie because of an inoperable primary liver cancer.
698) Lippman SM et al, Invest New Drugs 6: 51-6, 1988, 13-cis-retinoic acid-brings with squamous cell carcinomas at an advanced stage regressions produce significantly more than on the spontaneous regression rate could be expected, this was not for the control group that received methotrexate.
699) Robinson E et al, Biomedicine 31 :8-10, 1979, a methanol extract of BCG improves disease-free survival and survival seconds of cancer patients Dukes B2 / C, surgery and radiation / chemo treatment, this result is consistent with many other trials with BCG as an additional adjuvant for cancer.
700) BP Xu et al, Zhongguo Zhong Xi Yi Jie He Za Zhi 23: 661-3, 2003; Jingming reduce vision problems associated with radiation due to nasopharynxcarcinoom.
